Rochefort

Researchers are studying Philadelphia-negative myeloproliferative neoplasms (MPN), which include Polycythemia Vera (PV), essential thrombocythemia (ET), and prefibrotic myelofibrosis (PreMF). These chronic blood cancers involve specific mutations like JAK2V617F and carry a high risk of blood clots that can cause serious health problems. Current treatments include low-dose aspirin to reduce arterial clots, but patients still face risks of thrombosis and bleeding. This trial explores whether direct oral anticoagulants (DOACs), such as Apixaban or Rivaroxaban, might better prevent these clotting events in patients with the JAK2V617F mutation. Participants will be randomly assigned to receive either a DOAC (Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once daily) or low-dose aspirin (100 mg once daily). The study focuses on high-risk MPN patients with JAK2V617F mutation and will compare the effectiveness and safety of DOACs versus aspirin for preventing blood clots. Treatment will continue with close monitoring throughout the study. During the study, researchers will track the time until any arterial or venous blood clots occur over a 24-month follow-up period. Participants will undergo regular assessments to monitor clotting events, bleeding risks, and overall health. The trial aims to gather detailed information on how well these treatments prevent thrombosis and their safety profiles, helping to guide future care for patients with these blood disorders.

This research aims to create the largest possible real-life group of patients with chronic myeloid leukemia (CML) to study their long-term health outcomes. The study focuses on collecting observational data to understand different patient subgroups based on their treatment responses, the effects of new medications used in everyday practice, treatment discontinuations, and how changes in medical recommendations impact patients. The study involves gathering clinical and biological information from patients with CML both prospectively and retrospectively, starting from diagnosis and continuing during long-term follow-up, even after treatment has stopped. There are no specific treatments or interventions being tested, as the study is observational and collects data from real-life patient experiences. Participants will have their clinical and biological data collected and monitored until death or the last follow-up visit, which may last up to 30 years. This allows researchers to observe how the disease and treatments evolve over time. The study does not involve procedures, but collects information to better understand CML in real-world settings and evaluate various outcomes related to patient care.

Researchers are conducting the Dataids cohort, a long-term prospective study involving over 30,000 HIV-infected patients receiving care at more than 15 HIV centers across France. The study aims to monitor clinical practices, track changes in the course of HIV and related infections, and evaluate factors influencing the clinical, immunological, and virological progression of HIV. It also focuses on assessing antiretroviral therapy (ART) effectiveness and monitoring hepatitis C virus (HCV) treatment outcomes. Participants in the study include HIV-1 infected patients regardless of their CD4 cell count or ART status. Data collection occurs as part of routine outpatient clinic visits, with annual gathering of demographic, immunological, virological, serological, laboratory, therapeutic, and clinical information. The cohort has been ongoing since 2010, reflecting real-world clinical care and treatment patterns in France. Throughout the study, researchers track participants’ HIV plasma viral load to evaluate treatment success, specifically measuring the proportion of patients with viral loads below 50 copies/mL over an average of six months from enrollment. Data on co-infections such as hepatitis B and C, as well as syphilis, are also collected. This observational design allows ongoing surveillance of HIV infection trends and treatment effectiveness, supporting improved care quality for HIV patients in France.